Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
54.32
-1.45 (-2.60%)
Official Closing Price
Updated: 7:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
November 01, 2024
On Friday, Bristol Myers Squibb stock earned an upgrade to its Relative Strength (RS) Rating, from 62 to 79.
Via
Investor's Business Daily
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
November 01, 2024
Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a robust neuropsych pipeline.
Via
Benzinga
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
November 01, 2024
The major indexes declined, but haven't fallen apart.
Via
Investor's Business Daily
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
October 23, 2024
Via
Benzinga
Unveiling 11 Analyst Insights On Bristol-Myers Squibb
October 07, 2024
Via
Benzinga
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
October 31, 2024
From
Bristol Myers Squibb
Via
Business Wire
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
October 31, 2024
Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months.
Via
Benzinga
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
October 31, 2024
BMY earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
October 31, 2024
Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis. Adjusted EPS of $1.80 beat estimates.
Via
Benzinga
Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance
October 31, 2024
The pharma giant has been trading tightly in recent weeks.
Via
Investor's Business Daily
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
October 31, 2024
From
Bristol Myers Squibb
Via
Business Wire
Markets Give Back Gains As Hovering Continues
October 30, 2024
Market indexes could not hold onto earlier gains this afternoon, and all closed near session lows. The moves were mild, though — as we’ve stated in this space previously, the big news the market is...
Via
Talk Markets
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via
Benzinga
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
October 30, 2024
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.
Via
Benzinga
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
October 28, 2024
From
Bristol Myers Squibb
Via
Business Wire
What Lies In Store For Healthcare ETFs In Q3 Earnings?
October 27, 2024
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited.
Via
Talk Markets
Topics
ETFs
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
October 23, 2024
EF Hutton rates ImmunityBio (IBRX) as a Buy with a $30 target. Anktiva shows promise in cancer treatment, boosting response rates and survival outcomes.
Via
Benzinga
Why Is Evotec Stock Gaining Today?
October 23, 2024
Evotec stock is up following progress in its partnership with Bristol Myers Squibb, including a $50 million payment.
Via
Benzinga
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
October 22, 2024
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.
Via
Talk Markets
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
October 18, 2024
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
Via
Investor's Business Daily
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
October 17, 2024
HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers...
Via
Benzinga
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?
October 16, 2024
Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.
Via
The Motley Fool
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
October 15, 2024
The company could have a long path ahead to reimbursement and, ultimately, sales.
Via
Investor's Business Daily
Exposures
Product Safety
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
October 12, 2024
Johnson & Johnson is a leader in the pharmaceutical, medical device, and consumer products industries. Here are some highlights from a quantitative analysis of the company's stock.
Via
Talk Markets
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
October 11, 2024
Perspective Therapeutics is down 13% at last check Friday. The downtrend comes as drug study results are presented to medical professionals.
Via
Benzinga
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
October 07, 2024
The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens doors for Reviva's brilaroxazine, a multi-receptor antipsychotic.
Via
Benzinga
Exposures
Product Safety
10 Health Care Stocks Whale Activity In Today's Session
October 07, 2024
Via
Benzinga
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
October 07, 2024
Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors.
Via
Benzinga
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
Pfizer Stock Slump: Will Starboard's Billion-Dollar Bet Spark Rebound?
October 07, 2024
Pfizer's stock has struggled due to declining demand for COVID-19 treatments, but activist investor Starboard's $1 billion stake may spark a turnaround.
Via
Benzinga
Exposures
COVID-19
Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
October 04, 2024
FDA approves Bristol Myers' Opdivo for resectable non-small cell lung cancer, reducing recurrence risk by 42% and showing 70% 18-month event-free survival in patients.
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.